Isolation and characterization of human anti‐acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci

• Published in: European journal of immunology 2005-06, Vol.35 (6), p.1960-1968
• Main Authors: Protopapadakis, Evdokia, Kokla, Anna, Tzartos, Socrates J., Mamalaki, Avgi
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Antibodies, Monoclonal - biosynthesis; Antibodies, Monoclonal - genetics; Antibodies, Monoclonal - therapeutic use; Base Sequence; Binding, Competitive; Enzyme-Linked Immunosorbent Assay; Genes, Immunoglobulin; Human acetylcholine receptor; Human monoclonal antibodies; Humans; Immunoglobulin Fab Fragments - biosynthesis; Immunoglobulin Variable Region - genetics; Mice; Mice, Transgenic; Molecular Sequence Data; Myasthenia gravis; Myasthenia Gravis - immunology; Rats; Receptors, Cholinergic - immunology; Transgenic humanized mice
• ISSN: 0014-2980; 1521-4141
• DOI: 10.1002/eji.200526173

The isolation of human antibodies against muscle acetylcholine receptor (AChR), the autoantigen involved in myasthenia gravis (MG), is important for the development of therapeutically useful reagents. Monovalent antibody fragments from monoclonal antibodies against the main immunogenic region (MIR) of AChR protect the receptor from the destructive activity of MG autoantibodies. Human anti‐AChR α‐subunit antibody fragments with therapeutic potential have been isolated using phage display antibody libraries. An alternative approach for obtaining human mAb has been provided by the development of humanized mice. In this report, we show that immunization of transgenic mouse strains with the extracellular domain of the human AChR α‐subunit results in antibody responses and isolation of hybridomas producing human mAb. Four specific IgM mAb were isolated and analyzed. mAb170 recognized the native receptor the best and was capable of inducing AChR antigenic modulation, suggesting its specificity for a pathogenic epitope. Moreover, the recombinant antigen‐binding (Fab) fragment of this mAb competed with an anti‐MIR mAb, revealing that its antigenic determinant lies in or near the MIR. Finally, Fab170 was able to compete with MG autoantibodies and protect the AChR against antigenic modulation induced by MG sera. This approach will be useful for isolating additional mAb with therapeutic potential against the other AChR subunits.